AGP
EWTX icon

Artia Global Partners’s Edgewise Therapeutics EWTX Stock Holding History

Artia Global Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$1.33M – 40
2024
Q4 		$1.33M Buy
+50,000
New +$1.59M 0.48% 32

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Artia Global Partners's EWTX Position: Q2 2026 in Review

Artia Global Partners increased its Edgewise Therapeutics (EWTX) stake by 51% in Q2 2026, buying an estimated $1.15M and bringing the position to 98,800 shares worth $4.01M. The position accounts for 0.74% of the portfolio, ranked #30.

Artia Global Partners first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Artia Global Partners held 98,800 shares of Edgewise Therapeutics worth $4.01M as of Q2 2026.
  • Artia Global Partners bought 33,300 Edgewise Therapeutics shares in Q2 2026, an estimated $1.15M.
  • Edgewise Therapeutics made up 0.74% of Artia Global Partners's portfolio in Q2 2026, its #30 holding.
  • Artia Global Partners first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.